Actively Recruiting

Phase 2
Phase 3
Age: 1Year - 17Years
All Genders
NCT07159841

A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)

Led by Crinetics Pharmaceuticals Inc. · Updated on 2026-04-30

153

Participants Needed

32

Research Sites

214 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of atumelnant treatment in pediatric participants with classic congenital adrenal hyperplasia (CAH).

CONDITIONS

Official Title

A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)

Who Can Participate

Age: 1Year - 17Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or female at birth, aged 1 to under 18 years at consent
  • Medically confirmed diagnosis of classic CAH due to 21-hydroxylase deficiency by accepted criteria
  • Elevated morning serum androstenedione (A4) above upper limit of normal before morning glucocorticoid dose
  • Stable supraphysiologic glucocorticoid replacement therapy for at least one month before screening
  • Compliance with glucocorticoid and mineralocorticoid replacement therapy as judged by investigator
  • Normal thyroid stimulating hormone and thyroxine levels within 3 months before screening
  • For Part C, completed Part A or B treatment and investigator believes continuing would benefit the participant
Not Eligible

You will not qualify if you...

  • Diagnosis of any form of CAH other than classic 21-hydroxylase deficiency
  • Treatment with other glucocorticoids within 30 days before screening
  • Stress-dose glucocorticoid therapy within 2 weeks before screening
  • Use of growth hormones within 1 week (short acting) or 6 weeks (long acting) before screening
  • Use of corticotropin-releasing factor receptor antagonist within 14 days before screening
  • History of cancer except cured skin or cervical carcinoma in situ
  • Abnormal sleep/wake cycles as determined by investigator
  • Female participants who are pregnant or breastfeeding
  • Use of investigational drugs (other than atumelnant) within 60 days or 5 half-lives before first dose
  • For Part C, not meeting Part C inclusion criteria

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 32 locations

1

University of Michigan

Ann Arbor, Michigan, United States, 48109

Actively Recruiting

2

University of Minnesota

Minneapolis, Minnesota, United States, 55454

Actively Recruiting

3

Rutgers Robert Wood Johnson Medical School

New Brunswick, New Jersey, United States, 08901

Actively Recruiting

4

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States, 19104

Actively Recruiting

5

Cook Children's Health Care System

Fort Worth, Texas, United States, 76104

Actively Recruiting

6

University of Virginia Health System

Charlottesville, Virginia, United States, 22903

Actively Recruiting

7

Instituto de Investigaciones Metabólicas

Buenos Aires, Buenos Aires, Argentina, C1012AAR

Actively Recruiting

8

Hospital de Niños de la Santísima Trinidad

Córdoba, Córdoba Province, Argentina, X5000

Actively Recruiting

9

Hospital Italiano de Buenos Aires

Buenos Aires, Argentina, C1199ABB

Actively Recruiting

10

Instituto Médico Especializado (IME)

Buenos Aires, Argentina, C1405BCH

Actively Recruiting

11

CEDIE "Centro de Investigaciones Endocrinológicas", CONICET-FEI División de Endocrinología, Hosp de Niños Ricardo Gutiérrez

Buenos Aires, Argentina, C1425EFD

Actively Recruiting

12

Institute of Endocrinology of Diabetes, The Children's Hospital at Westmead

Westmead, New South Wales, Australia, 2145

Not Yet Recruiting

13

Queensland Children's Hospital

South Brisbane, Queensland, Australia, 4101

Not Yet Recruiting

14

Monash Children's Hospital, Monash Health

Clayton, Victoria, Australia, 3168

Actively Recruiting

15

UZA (Antwerp University Hospital)

Edegem, Antwerp, Belgium, 2650

Actively Recruiting

16

UZ Gent (University Hospital Ghent)

Ghent, East Flanders, Belgium, 9000

Actively Recruiting

17

UZ Leuven (Universitair Ziekenhuis Leuven)

Leuven, Flemish Brabant, Belgium, 3000

Actively Recruiting

18

Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP)

São Paulo, São Paulo, Brazil, 05403-000

Actively Recruiting

19

Centre Hospitalier Universitaire (CHU) d'Angers

Angers, France, 49100

Actively Recruiting

20

Hopital Kremlin-Bicétre - APHP Paris Saclay

Le Kremlin-Bicêtre, France, 94270

Actively Recruiting

21

Hopital Jeanne de Flandre - CHU de Lille

Lille, France, 59037

Actively Recruiting

22

APHM -Hopital La Timone Enfants

Marseille, France, 13385 Cedex 5

Actively Recruiting

23

Hopital Necker - Enfants Malades

Paris, France, 75015

Actively Recruiting

24

Hopital Robert Debre

Paris, France, 75019

Actively Recruiting

25

Charité - Universitätsmedizin Berlin Campus Virchow-Klinikum Klinik für pädiatrische Endokrinologie und Diabetologie

Berlin, Germany, 13353

Actively Recruiting

26

AOU Federico II

Naples, Campania, Italy, 80131

Actively Recruiting

27

IRCCS Istituto Giannina Gaslini

Genoa, Liguria, Italy, 16147

Actively Recruiting

28

IRCCS Ospedale San Raffaele

Milan, Lombardy, Italy, 20132

Actively Recruiting

29

Azienda Ospedaliera Universitaria Meyer IRCCS

Florence, Tuscany, Italy, 50139

Actively Recruiting

30

lnstytut Centrum Zdrowia Matki Polki, Klinika Endokrynologii i Chor6b Metabolicznych

Lodz, Poland, Poland, 93-338

Actively Recruiting

31

Uniwersytecki Szpital Kliniczny Nr 1 im. Prof. Tadeusza Sokotowskiego PUM w Szczecinie, Centrum Wsparcia Badan Klinicznych Pomorskiego Uniwersytetu Medycznego w Szczecinie

Szczecin, West Pomeranian Voivodeship, Poland, 71-252

Actively Recruiting

32

Sheffield Children's Hospital NHS Trust, Sheffield Children's Hospital, Western Bank

Sheffield, United Kingdom, S10 2TH

Actively Recruiting

Loading map...

Research Team

C

Crinetics Clinical Trials

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

SEQUENTIAL

Primary Purpose

TREATMENT

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here